Cellectar Biosciences Inc’s filing revealed that its Chief Operating Officer Longcor Jarrod acquired Company’s shares for reported $8400.0 on Jan 10 ’25. In the deal valued at $0.28 per share,30,000 shares were bought. As a result of this transaction, Longcor Jarrod now holds 83,141 shares worth roughly $19953.84.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Tuesday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock fall -9.13% to $0.24. Over the last five days, the stock has lost -0.33%. Cellectar Biosciences Inc shares have fallen nearly -19.73% since the year began. Nevertheless, the stocks have fallen -92.59% over the past one year. While a 52-week high of $3.49 was reached on 03/20/25, a 52-week low of $0.22 was recorded on 01/15/25. SMA at 50 days reached $0.3007, while 200 days put it at $1.1017.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 0.2300, which if violated will result in even more drops to 0.2200. On the upside, there is a resistance level at 0.2600. A further resistance level may holdings at 0.2800. The Relative Strength Index (RSI) on the 14-day chart is 38.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0174, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.12%. Stochastics %K at 18.24% indicates the stock is a buying.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
